DAFTAR PUSTAKA

Afkarian, M., Zelnick, L. R., Hall, Y. N., Heagerty, P. J., Tuttle, K., Weiss, N. S., & de Boer, I. H. (2016). Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. *JAMA, 316(6), 602.* http://doi.org/10.1001/jama.2016.10924

American Diabetes Association. (2020). Standards of Medical Care in Diabetes—2020 Abridged for Primary Care Providers. *Clinical Diabetes, 38(1), 10–38.* https://doi.org/10.2337/cd20-as01

American Diabetes Association. (2018). 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018. *Diabetes Care, 41(Supplement_1), S13–S27.* https://doi.org/10.2337/dc18-S002

American Diabetes Assosiation. (2014). Diagnosis and classification of diabetes mellitus. *Diabetes Care, 37(SUPPL.1).* https://doi.org/10.2337/dc14-S081

American Diabetes Association. (2013). *Economic Costs of Diabetes in the U.S. in 2012*. Diabetes Care, 36(4), 1033-1046: http://doi.org/10.2337/dc12-2625

Andayani, T. M. (2013). *Farmakoekonomi: Prinsip dan Metodologi.* Yogyakarta: Bursa Ilmu.

Anis, C., Sekeon, S. A. S., & Kandou, G. D. (2017). *Hubungan Antara Diabetes Melitus (Hiperglikemia) Dengan Kualitas Hidup Pada Lansia Di Kelurahan Kolongan, Kecamatan Tomohon Tengah, Kota Tomohon*.

Arnold, R. J. G. (2016). *Pharmacoeconomics From Theory to Practice*. CRC Press.

Azoulay, L., & Suissa, S. (2017). Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies. *Diabetes Care, 40(5), 706-714.* http://doi.org/10.2337/dc16-1943

Bahendeka, S., Wesonga, R., Mutungi, G., Muwonge, J., Neema, S., & Guwatudde, D. (2016). Prevalence and correlates of diabetes mellitus in Uganda: a population-based national survey. *Tropical Medicine & International Health, 21(3), 405–416*. https://doi.org/10.1111/tmi.12663

Banday, M. Z., Sameer, A. S., & Nissar, S. (2020). Pathophysiology of diabetes: An overview. *Avicenna Journal of Medicine, 10(04), 174–188.* https://doi.org/10.4103/ajm.ajm_53_20

Corcoran, C., & Jacobs, T. F. (2023). *Metformin*.

Costello, R. A., Nicolas, S., & Shivkumar, A. (2023). *Sulfonylureas*.

Desianti, S., Dan, K., & Lestari, K. (2018). *Review Artikel: Kajian Farmakoekonomi yang Mendasari Pemilihan Pengobatan di Indonesia*.

DiNicolantonio, J. J., Bhutani, J., & O'Keefe, J. H. (2015). Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. *Open Heart, 2(1), e000327.* http://doi.org/10.1136/openhrt-2015-000327

Fatimah, R. N. (2015). Diabetes Melitus Tipe 2. *J MAJORITY, 4*.

Faza, F., Maulina, N., Sugihantoro, H., Muhimmah, I., & Saputra, A. F. (2022). Analisis Efektivitas Biaya Penggunaan Antidiabetik Oral pada Pasien Diabetes Melitus Rawat Jalan di RSU Haji Surabaya. *Pharmaceutical Journal Of Indonesia 2022, 8(1), 49–58.* http://.pji.ub.ac.id

Fitria. (2018). *Analisis Efektivitas Biaya Dan Minimalisasi Biaya Pada Penderita Diabetes Melitus Tipe 2 Di Instalasi Rawat Inap RSUP Dr. Wahidin Sudirohusodo Makassar 2018*.

Fitriyani, F., Andrajati, R., & Trisna, Y. (2021). Analisis Efektivitas-Biaya Terapi Kombinasi Metformin-Insulin dan Metformin-Sulfonilurea pada Pasien Rawat Jalan dengan Diabetes Melitus Tipe 2 di RSUPN Dr. Cipto Mangunkusumo. *Indonesian Journal of Clinical Pharmacy, 10(1), 10.* https://doi.org/10.15416/ijcp.2021.10.1.10

Flory, J. H., Small, D. S., Cassano, P. A., Brillon, D. J., Mushlin, A. I., & Hennessy, S. (2014). Comparative effectiveness of oral diabetes drug combinations in reducing glycosylated hemoglobin. J*ournal of Comparative Effectiveness Research, 3(1), 29-39.* http://doi.org/10.2217/cer.13.87

Goyal, R., & Jialal, I. (2023). *Type 2 Diabetes*.

Hammer, G. D., & McPhee, S. I. (2014). *Pathophysiology of Disease: An Introduction to Clinical Medicine.*

Hartini, S. (2016). Hubungan HBA1c Terhadap Kadar Glukosa Darah Pada Penderita Diabetes Mellitus Di RSUD Abdul Wahab Syahranie Samarinda Tahun 2016. *Jurnal Husada Mahakam, IV(3)*, 171–180.

Huang, D., Refaat, M., Mohammedi, K., Jayyousi, A., Al Suwaidi, J., & Abi Khalil, C. (2017). Macrovascular Complications in Patients with Diabetes and Prediabetes. *BioMed Research International, 2017, 1-9.* http://doi.org/10.1155/2017/7839101

Imelda, S. (2019). Faktor-Faktor Yang Mempengaruhi Terjadinya diabetes Melitus di Puskesmas Harapan Raya Tahun 2018. *Scientia Journal, 8(1).* https://doi.org/10.5281/scj.v8i1.406

Indrayathi, P. A., & Noviyanti, R. (2016). *Cost Of Illness (Beban Ekonomi Penyakit Dalam Pembangunan Kesehatan)*.

International Diabetes Federation. (2021). *IDF Diabetes Atlas 10th edition*. www.diabetesatlas.org

Isnani, N., Muliyani, M., Zaini, M., & Arif Riyadi, M. (2021). Analisis Efektivitas Biaya (Cost-Effectiveness) Penggunaan Antidiabetes Oral Kombinasi pada Pasien Diabetes Melitus Tipe II Rawat Jalan di RSUD Dr. H. Moch. Ansari Saleh Banjarmasin. J*urnal Insan Farmasi Indonesia, 4(1), 103–110.* https://doi.org/10.36387/jifi.v4i1.683

Kampmann, U. (2015). Gestational diabetes: A clinical update. *World Journal of Diabetes, 6(8), 1065.* http://doi.org/10.4239/wjd.v6.18.1065

Kalra, S., Mukherjee, J., Ramachandran, A., Saboo, B., Shaikh, S., Venkataraman, S., Das, A. (2013). Hypoglycemia: The neglected complication. *Indian Journal of Endocrinology and Metabolism, 17(5), 819.* http://doi.org/10.4103/2230- 8210.117219

Kautzky-Willer, A., Leutner, M., & Harreiter, J. (2023). Correction to: Sex differences in type 2 diabetes. *Diabetologia, 66(6), 1165–1165.* https://doi.org/10.1007/s00125-023-05913-8

Kautzky-Willer, A., Harreiter, J., & Pacini, G. (2016). Sex and Gender Differences in Risk, Pathophysiology and Complications of Type 2 Diabetes Mellitus. *Endocrine Reviews, 37(3), 278–316.* https://doi.org/10.1210/er.2015-1137

Kedia. (2011). Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 337.* http://doi.org/10.2147/DMSO.S20633

Kementerian Kesehatan RI. (2020). *Infodatin 2020 Diabetes Melitus*. Jakarta: Kementerian Kesehatan RI.

Kementerian Kesehatan RI. (2015). *Direktorat Jenderal Bina Kefarmasian dan Alat Kesehatan Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/523/2015 tentang Formularium Nasional*. Jakarta: Kementerian Kesehatan RI.

Kementerian Kesehatan RI. (2013). *Pedoman Penerapan Kajian Farmakoekonomi*. Kementerian Kesehatan RI.

Khairinnisa, A., Yusmaini, H., & Hadiwiardjo, Y. H. (2020). Perbandingan Penggunaan Glibenclamid-Metformin dan Glimepirid-Metformin Terhadap Efek Samping Hipoglikemia Pasien Diabetes Melitus Tipe-2 di Kota Tangerang Selatan. *Seminar Nasional Riset Kedokteran*.

Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009). Hyperglycemic crises in adult patients with diabetes. *Diabetes Care, 32(7), 1335–1343.* https://doi.org/10.2337/dc09-9032

Lee, Y.K., Song, S. O., Kim, K. J., Cho, Y., Choi, Y., Yun, Y., ... Lee, H. C. (2013). Glycemic Effectiveness of Metformin-Based Dual-Combination Therapies with Sulphonylurea, Pioglitazone, or DPP4-Inhibitor in Drug-Naive Korean Type 2 Diabetic Patients. *Diabetes & Metabolism Journal, 37(6), 465.* http://doi.org/10.4093/dmj.2013.37.6.465

Lin, L.-K., Sun, Y., Heng, B. H., Chew, D. E. K., & Chong, P.-N. (2017). Medication adherence and glycemic control among newly diagnosed diabetes patients. *BMJ Open Diabetes Research & Care, 5(1), e000429.* https://doi.org/10.1136/bmjdrc-2017-000429

Lin, S.-D., Wang, I.-S., Hsu, S.-R., Sheu, W. H.-H., Tu, S.-T., Lee, L.-T., ... Hsich, M.- C. (2011). The beneficial effect of a-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. *Journal of Diabetes and Its Complications, 25(5), 332-338.* http://doi.org/10.1016/j.jdiacomp.2011.06.004

Liu, X., Zeng, L., & Xu, W. (2018). Pharmacoeconomic evaluation of glimepiride combined with other drugs in the treatment of diabetes. *Pakistan Journal of Pharmaceutical Sciences, 31(3(Special))*, 1103–1107.

Maulina Hutabarat, U., Hasneli, Y., & Erwin. (2018). Hubungan Komplikasi Diabetes Mellitus dengan Kualitas Hidup Pasien Diabetes Mellitus. *JOM FKp, 5(2).*

Milita, F., Handayani, S., & Setiaji, B. (2021). Kejadian Diabetes Mellitus Tipe II pada Lanjut Usia di Indonesia (Analisis Riskesdas 2018). *Jurnal Kedokteran Dan Kesehatan*. https://jurnal.umj.ac.id/index.php/JKK

Mozaffarian, D., Benjamin, E. J., Go, A. S., Arnett, D. K., Blaha, M. J., Cushman, M., & Turner, M. B. (2016). Executive Summary: Heart Disease and Stroke Statistics-2016 Update. *Circulation, 13(4),447-454:* http://doi.org/10.1161/CIR.0000000000000366

Muhammad, A. A. (2018). Resistensi Insulin dan Disfungsi Sekresi Insulin Sebagai Faktor Penyebab Diabetes Melitus Tipe 2. *Jurnal Kesehatan Masyarakat*, 8(2). https://doi.org/https://doi.org/10.56338/pjkm.v8i2.631

Murtiningsih, M. K., Pandelaki, K., & Sedli, B. P. (2019). Gaya Hidup sebagai Faktor Risiko Diabetes Melitus Tipe 2. *Ejournal Unsrat*. https://doi.org/10.35790/ecl.9.2.2021.32852

Nasri, H., & Rafieian-Kopaei, M. (2014). Metformin: Current knowledge. *Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences, 19(7)*, 658–664.

Notoadmojo, S. 2012. *Metodologi Penelitian Kesehatan.* Jakarta: Rhineka Cipta.

Nurul Jannah, E., Ismunandar, A., Hidayat Maulana, L., Studi Farmasi, P., Sains dan Teknologi, F., & Peradaban, U. (2021). *Analisis Efektivitas Biaya Penggunaan Antidiabetik Oral Pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan Peserta BPJS di RSUD Bumiayu 2020*. *1*(2).

Oktaliani, R., & Zamri, A. (2019). *Hyperosmolar Hyperglycemic State (HHS)*.

PIO Nas. (2015a). *Akarbosa*. Retrieved May 22, 2023, from http://pionas.pom.go.id/monografi/akarbosa

PIO Nas. (2015b). *Metformin Hidroklorida*. Retrieved May 22, 2023 from http://pionas.pom.go.id/monografi/metformin-hidroklorida

Prabawati, D., Rostiana, D., & Wiwiek Subekti, O. (2023). *Waspadai Prediabetes dan Cegah Gaya Hidup Sedentary pada Usia Remaja* (Vol. 1, Issue 1).

Pratiwi, W., Harfiani, E., & Hadiwiardjo, Y. H. (2020). Faktor-Faktor Yang Berhubungan Dengan Kepatuhan Dalam Menjalani Pengobatan Pada Penderita Hipertensi Di Klinik Pratama GKI Jabar Jakarta Pusat. *Seminar Nasional Riset Kedokteran*.

Raharjaputra, HS (2009). *Manajemen Keuangan dan Akuntansi.* Jakarta: Salemba Empat.

Rascati, K. L. (2014). *Essentials of Pharmacoeconomics* (2nd ed.). Philadelphia: L,ippincott Williams & Wilkins.

Razzouk, D. (2017). Mental health economics: The costs and benefits of psychiatric care. In *Mental Health Economics: The Costs and Benefits of Psychiatric Care*. Springer International Publishing. https://doi.org/10.1007/978-3-319-55266-8

Rewers, A. (2017). Acute Metabolic Complications in Diabetes. In C. C. Cowie, S. S. Casagrande, A. Menke, M. A. Cissell, M. S. Eberhardt. J. B. Meigs, ... J. E. Fradkin (Eds.), *Diabetes in America (3rd ed., p. 1468).* Bethesda, MD: National Institutes of Health, NIH Pub No. 17.

Riddle, M. C. (2017). Modern Sulfonylureas: Dangerous or Wrongly Accused? *Diabetes Care, 40(5), 629-631.* http://doi.org/10.2337/dcil 7-0003

Rivano Ramadhan, I., Syurya, W., & Dharma, T. (2020). Analisis Efektivitas Biaya Obat Antidiabetik Monoterapi Dan Kombinasi Pada Pasien Diabetes Melitus Tipe Ii Peserta Bpjs Pasien Rawat Inap di Rumah Sakit Islam Cempaka Putih Jakarta Periode 2018. In *Social Clinical Pharmacy Indonesia Journal* (Vol. 5, Issue 1).

Rosak, C., & Mertes. (2012). Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 357.* http://doi.org/10.2147/DMSO.528340

RSPAD Gatot Soebroto. (2017). *Data 10 Besar Penyakit Rawat Jalan Tahun 2017.* Jakarta.

RSPAD Gatot Soebroto. (2023). *Visi dan Misi.* Jakarta.

Sartika, F., & Hestiani, N. (2019). Kadar Hba1C pada Pasien Wanita Penderita Diabetes Mellitus Tipe 2 di RSUD Dr. Doris Sylvanus Palangka Raya. *Borneo Journal Of Medical Laboratory Technology, 2(1)*.

Singh, S. (2018). Commentary on "Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: International Task Force." *Indian Journal of Endocrinology and Metabolism, 22*(1), 158. https://doi.org/10.4103/ijem.IJEM_22_18

Soebagijo Adi. (2021). *Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 Dewasa di Indonesia 2021*. PB PERKENI.

Sola, D., Rossi, L., Schianca, G. P. C., Maffioli, P., Bigliocca, M., Mella, R., ... Derosa, G. (2015). State of the art paper Sulfonylureas and their use in clinical practice. *Archives of Medical Science, 4, 840-848.* http://doi.org/10.5114/a0ms.2015.53304

Solichah, A. L. (2007). *Analisis Efektivitas-Biaya Sulfonilurea-Biguanid Dibandingkan Sulfonilurea-Alpha Glukosidase Inhibitor pada Pasien Diabetes Mellitus Tipe 2 Rawat Jalan Dirsup Dr. Sardjito Yogyakarta Tahun 2006.* Universitas Islam Indonesia.

Suhaida, F. T., Supartono, B., Savitri, P. M., & Rifkia, V. (2022). Hubungan Derajat Penyakit Osteoartritis Lutut dengan Neutrophil Lymphocyte Ratio pada Pasien di RSU Al Fauzan Jakarta Periode 2019-2021. J*urnal Ilmu Kedokteran (Journal of Medical Science), 16*(2), 108. https://doi.org/10.26891/JIK.v16i2.2022.108-114

Sukmawan, Y. P. (2019). Metformin/Glimepiride and Metformin/Glibenclamide, Which is Better?: A Systematic Review and Meta-Analysis. *Indonesian Journal of Medicine, 4(3), 211–218*. https://doi.org/10.26911/theijmed.2019.04.03.03

Sulistyo, G., & Mutiara, H. (2015). Pemeriksaan Kadar HbA1c pada Pasien Diabetes Melitus Tipe 2 dengan Obesitas. *Agromed Unila*.

Sumiati, L, Citraningtyas, G & Yudistira, A. (2018). *Analisis efektivitas biaya terapi antihipertensi pada pasien hipertensi rawat inap di RSUD Pancaran Kasih GMIM Manado.* Pharmacon, Manado 7(1). https://ejournal.unsrat.ac.id/index.php/pharmacon/article/view/18723/18265

Tetuko, A., & Nugraheni, A. (2021). *Analisis Efektifitas Biaya Kombinasi Antidiabetik Oral pada Pasien Rawat Jalan Diabetes Melitus Tipe 2*. http://cjp.jurnal.stikescendekiautamakudus.ac.id

Tramunt, B., Smati, S., Grandgeorge, N., Lenfant, F., Arnal, J.-F., Montagner, A., & Gourdy, P. (2020). Sex differences in metabolic regulation and diabetes susceptibility. *Diabetologia, 63(3), 453–461.* https://doi.org/10.1007/s00125-019-05040-3

Trask, L. (2011). Pharmacoeconomics: Principles, Methods, and Applications. In J. T. DiPiro, R. L. Talbert, G. C. Yee, G. R. Matzke, B. G. Wells, & L. Posey (Eds.), *Pharmacotherapy: A Pathophysiologic Approach (8th ed.).* New York: McGraw-Hill.

Usman, J., Rahman, D., & Sulaiman, N. (2020). Faktor yang Berhubungan dengan Kejadian Diabetes Mellitus pada Pasien di RSUD Haji Makassar. J*urnal Komunitas Kesehatan Masyarakat, 2(1).*

Vadila, A., Dody Izhar, M., & Suryani Nasution, H. (2021). *Faktor-Faktor Kejadian Diabetes Melitus Tipe 2 di Puskesmas Putri Ayu. Media Kesehatan Politeknik Kesehatan Makassar.* https://doi.org/10.32382/medkes.v16i2.2282

Wang, H., & Chow, S. (2014). Sample Size Calculation for Comparing Proportions. In *Wiley StatsRef: Statistics Reference Online*. Wiley. https://doi.org/10.1002/9781118445112.stat07091

Wang, J.-S., Huang, C.-N., Hung, Y.-J., Kwok, C.-F., Sun, J.-H., Pei, D., ... Sheu, W. H.-H. (2013). Acarbose plus metformin fixed-dose combination outperforms acarbose monotherapy for type 2 diabetes. *Diabetes Research and Clinical Practice, 102(1), 16-24*. http://doi.org/10.1016/j.diabres.2013.08.001

Weng, J., Soegondo, S., Schnell, O., Sheu, W. H. -H., Grzeszczak, W., Watada, H., Yamamoto, N., & Kalra, S. (2015). Efficacy of acarbose in different geographical regions of the world: analysis of a real-life database. *Diabetes/Metabolism Research and Reviews, 31*(2), 155–167. https://doi.org/10.1002/dmrr.2576

World Health Organization. (2003). *Introduction to Drug Utilization Research*. https://www.who.int/publications/i/item/8280820396

Zhang, F., Xu, S., Tang, L., Pan, X., & Tong, N. (2020). Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. *Frontiers in Endocrinology*, *11*. https://doi.org/10.3389/fendo.2020.00288

Zhuo Xiaohui, Zhang Ping, Barker Lawrence, Albright Ann, Thompson Theodore J., & Gregg Edward. (2014). *The Lifetime Cost of Diabetes and Its Implications for Diabetes Prevention*. 37(9), 2557-2564: https://doi.org/10.2337/dc13-2484